BONUS CAP ZERTIFIKAT - GILEAD SCIENCES | Market Closed - Boerse Frankfurt Warrants 18:54:46 28/05/2024 BST | ||
| 57.52 EUR | -2.61% |
|
| Current month | -3.51% | ||
| 1 month | -4.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 57.52 | -2.61% |
| 27/05/24 | 59.06 | +0.22% |
| 24/05/24 | 58.93 | -1.49% |
| 23/05/24 | 59.82 | -2.13% |
| 22/05/24 | 61.12 | +1.14% |
Real-time Boerse Frankfurt Warrants
Last update May 28, 2024 at 06:54 pm
More quotesStatic data
| Product type | Certificati Bonus e Protezione parz. |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VM8B7M |
| ISIN | DE000VM8B7M6 |
| Date issued | 10/01/2024 |
| Strike | 100 $ |
| Maturity | 20/09/2024 (115 Days) |
| Parity | 1 : 1 |
| Emission price | 81.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 82.45 € |
|---|---|
| Lowest since issue | 57.52 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.68
USD
Average target price
82.77
USD
Spread / Average Target
+26.03%
- Stock Market
- Certificates
- Certificat
